Huadong Medicine completed the acquisition of Sinclair Pharma for $222m.

Huadong Medicine, a Chinese pharmaceutical company, completed the acquisition of Sinclair Pharma, a global aesthetics company, for $222m. “This is a significant and exciting opportunity for Sinclair Pharma, positioning us to expand our global operation that aims to be one of the leaders in aesthetics. We continue our commitment to be partners to physicians and to enriching our portfolio with unique, innovative aesthetics products and procedures,” Chris Spooner, Sinclair Chief Executive Office